Step 1 topics → Respiratory → Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

USMLE Step 1 trap: Misclassifies IPF as obstructive rather than restrictive on PFTs. IPF causes a restrictive pattern (reduced TLC, FVC, DLCO) with preserved or elevated FEV1/FVC ratio due to stiff, non-compliant lungs.

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrotic lung disease with a median survival of 3-5 years from diagnosis. It's the prototypical usual interstitial pneumonia (UIP) pattern — a histologic and radiologic designation that carries major clinical implications. USMLE Step 1 tests IPF from multiple angles: recognizing the classic demographic (older male smoker with exertional dyspnea and dry cough), interpreting PFTs correctly, identifying HRCT findings, and knowing what the treatment actually is versus what students incorrectly default to.

The trickiest part of IPF for most students is threefold. First, many students misclassify the PFT pattern as obstructive — the word 'fibrosis' makes them think of trapped air, but stiff fibrotic lungs can't expand, making it purely restrictive. Second, students confuse UIP with uniform fibrosis, but the defining feature is heterogeneity — normal lung sitting next to honeycombing next to fibrosis, concentrated subpleurally and at the bases. Third, students reflexively reach for corticosteroids because they associate interstitial lung disease with inflammation. IPF is a fibrotic process, not primarily inflammatory, and steroids do not help.

On USMLE Step 1, IPF questions often present a clinical vignette — older man, bilateral basal crackles, clubbing, restrictive PFTs, HRCT showing honeycombing — and ask you to identify the diagnosis, interpret the imaging, or select the correct management. Know that a classic HRCT pattern (subpleural, basal honeycombing with traction bronchiectasis) is sufficient to diagnose IPF without surgical biopsy when clinical context fits. Pirfenidone and nintedanib slow progression; nothing reverses it.

From real student decks
76%have cards covering this topic
73%have mature cards

Well-covered in most decks — the challenge is retention, not exposure.

Common misconceptions

Common mistake
Wrong: IPF causes an obstructive pattern on PFTs because fibrosis traps air.
Right: IPF causes a restrictive pattern (reduced TLC, FVC, DLCO) with preserved or elevated FEV1/FVC ratio due to stiff, non-compliant lungs.
Fibrosis makes the lung stiffer and smaller, not air-trappy. The lungs can't fully expand, so TLC and FVC fall — that's restriction by definition. The FEV1/FVC ratio is preserved or even elevated because both compartments shrink proportionally and stiff airways actually recoil faster. Any time you see fibrosis on Step 1, think restriction and reduced DLCO (because the thickened alveolar-capillary membrane impairs gas exchange).
Common mistake
Wrong: UIP pattern is characterized by uniform, diffuse fibrosis throughout the lung.
Right: UIP pattern is defined by temporal and spatial heterogeneity — areas of normal lung, fibrosis, and honeycombing coexist — with subpleural, basal predominance.
UIP is defined by its patchwork appearance, not uniform involvement. On biopsy, you see regions of completely normal lung directly adjacent to dense fibrosis and honeycombing — this is the 'temporal heterogeneity' (lesions at different stages of evolution coexisting). This is what distinguishes UIP from NSIP, which has uniform, diffuse ground-glass involvement and a better prognosis. The subpleural, basal-predominant distribution is equally important to recognize on HRCT.
Common mistake
Wrong: Corticosteroids are the mainstay of IPF treatment because it is an inflammatory disease.
Right: Corticosteroids are not beneficial in IPF and may be harmful; antifibrotic agents (pirfenidone or nintedanib) are the disease-modifying treatments.
IPF is fundamentally a fibrotic disease driven by aberrant wound healing, not an inflammatory disease. Corticosteroids work by suppressing inflammation, so they don't target the underlying pathology in IPF. Clinical trials have shown no benefit and potential harm from steroids in IPF. The disease-modifying agents — pirfenidone (an antifibrotic) and nintedanib (a tyrosine kinase inhibitor) — slow the rate of FVC decline but don't reverse established fibrosis.
Common mistake
Gap: Fails to recognize that classic HRCT findings can obviate the need for surgical biopsy in IPF diagnosis
A typical UIP pattern on HRCT (subpleural, basal honeycombing with traction bronchiectasis) is sufficient to diagnose IPF without surgical lung biopsy in the right clinical context.
This is a high-yield diagnostic principle: when HRCT shows the classic UIP pattern (subpleural and basal honeycombing ± traction bronchiectasis) in the right clinical context (older patient, no alternative cause identified), that imaging alone is sufficient for IPF diagnosis. Surgical lung biopsy is reserved for cases where HRCT findings are atypical or indeterminate. Recognizing this prevents both under-diagnosis and unnecessary invasive procedures on the exam.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Identify the histologic hallmarks of UIP pattern — temporal and spatial heterogeneity, honeycombing, fibroblastic foci — and understand what distinguishes UIP from other fibrotic patterns like NSIP.
  2. Recognize the classic IPF presentation: older male, history of smoking, progressive exertional dyspnea, dry cough, bilateral basal Velcro crackles, digital clubbing, and a restrictive PFT pattern with reduced TLC, FVC, and DLCO but preserved or elevated FEV1/FVC ratio.
  3. Interpret HRCT findings consistent with UIP pattern — subpleural, basal-predominant honeycombing with traction bronchiectasis — and understand when these findings are sufficient to diagnose IPF without surgical lung biopsy.
  4. Select the correct disease-modifying treatment for IPF (pirfenidone or nintedanib), know that corticosteroids are not indicated and may be harmful, and understand that prognosis is poor with no curative medical therapy available.

Can you avoid these mistakes?

A 68-year-old man with a 40-pack-year smoking history presents with 2 years of progressive dyspnea and dry cough. Exam shows bilateral basal inspiratory crackles and clubbing. PFTs show FVC 62% predicted, TLC 65% predicted, FEV1/FVC 0.84, DLCO 55% predicted. What pattern do these PFTs represent, and what is the most likely diagnosis?
A pathologist describes a lung biopsy showing areas of normal parenchyma adjacent to dense collagen fibrosis and honeycombing, with fibroblastic foci, concentrated in the subpleural regions. What histologic pattern is this, and how does it differ from NSIP?
HRCT of a 71-year-old woman with progressive exertional dyspnea shows bilateral, subpleural, basal-predominant honeycombing with traction bronchiectasis. No occupational exposure or connective tissue disease is identified. Does this patient need a surgical lung biopsy to confirm IPF, and why or why not?
A patient is diagnosed with IPF. A colleague suggests starting prednisone to slow disease progression. What is wrong with this approach, and what medications should actually be offered?

Related topics

PFT Patterns — Obstructive vs Restrictive Lung Development Stages Surfactant Production and Neonatal RDS Bronchopulmonary Dysplasia Congenital Diaphragmatic Hernia

See how your Anki deck covers this topic.

Upload your deck for a free audit →